Oral Simufilam Slowed Cognitive Decline in a Randomized
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild...
Source: globenewswire.com
📰 Eric Schoen News
Page 3 - Eric Schoen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Schoen. Real-time updates on events, politics, business and more.
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer's Disease
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild...
Source: marketscreener.com
New Research Shows Simufilam Suppresses Overactive mTOR
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease.Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.Research is Published in Frontiers in Aging, a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2023 (GLOBE ...
United States Lindsay Burns Remi Barbier Eric Schoen Research Is Published In Frontiers Neuroscience At Cassava Sciences
Source: marketscreener.com
New Publication Highlights Basic Science Supporting Simufilam
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas,... | June 12, 2023
United States Lindsay Burns Eric Schoen Cassava Sciences Cassava Sciences Inc Drug Development Research
Source: marketscreener.com
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
AUSTIN, Texas, June 01, 2023 -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present... | June 1, 2023
New York United States Eric Schoen Cassava Sciences Cassava Sciences Inc Jefferies Global Healthcare Conference
Source: marketscreener.com
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer's Disease
The Cognition Maintenance Study is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition... | May 11, 2023
United States Eric Schoen Remi Barbier Cassava Sciences Inc Cassava Sciences Cognition Maintenance Study
Source: marketscreener.com
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
New in vitro data from Europe show that simufilam can reverse altered filamin A protein in pituitary tumor cells, leading to improved cell signaling.Data suggest FLNA is a central factor influencing... | May 8, 2023
United States Giovanna Mantovani Erika Peverelli Granda Ospedale Maggiore Policlinico Eric Schoen Remi Barbier
Source: marketscreener.com
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
01.05.2023 - Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 ...
Source: wallstreet-online.de
Cassava Sciences Announces Patient Enrollment Update for
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete...
Source: globenewswire.com
Cassava Sciences Announces Completion of Dosing in
Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical...
Source: globenewswire.com